Search

You searched for " prostate cancer"

140 results found

Use of MRI in the evaluation of prostate cancer: part 1

1 January 2015 | | URO - Urologic Oncology, URO - Uroradiology
Introduction Prostate cancer remains the most commonly diagnosed cancer in males and the second leading cause of cancer related deaths in UK men, after lung cancer [1]. The incidence of prostate cancer in the UK has shown a rapid increase...

Patient-reported outcomes after prostate cancer treatment

1 January 2015 | | URO - Urologic Oncology
This study used the survivorship (LIVESTRONG) care plan tool to identify patient-reported toxicities that occurred following treatment for prostate cancer. All patients had undergone treatments, which were considered to have similar oncological endpoints. The tool asked patients questions with regard...
European Urology journal front cover.

Cost effectiveness of prostate cancer screening in Europe

2 May 2025 | | URO - Urologic Oncology
Prostate cancer (PCa) stands as the most prevalent cancer and the third leading cause of cancer-related deaths among men in Europe. According to data from the European Commission, in 2020, PCa represented a staggering 23.2% of all new cancer cases...

Rishi Sunak joins Prostate Cancer Research as an ambassador

26 February 2025 | Charities, Research & Development
Rishi Sunak with three prostate cancer patients at the Oxford BioDynamics labs. (From left to right: Dafydd Charles, Briane Milne, Rishi Sunak, Alfred Samuels). Former UK Prime Minister Rishi Sunak has joined Prostate Cancer Research as an ambassador, to champion...

Prostate cancer management 1 – non-metastatic disease

2 May 2025 | | URO - Urologic Oncology, URO - Core Urology, URO - Uroradiology
You are referred a 68-year-old gentleman to the rapid access prostate clinic with a serum prostate specific antigen (PSA) of 12ug/L. He is otherwise fit and well with mild voiding lower urinary tract symptoms (LUTS). He undergoes a multi parametric...

Prostate Cancer Diagnosis – PSA, Biopsy and Beyond

1 September 2015 | | URO - Basic Science Research, URO - Urologic Oncology
The danger of many of the texts which deal with this rapidly changing field is that by the time the texts are published they are out of date. This book however remains fresh, in part because it acknowledges that there...

Recent advances in the management of castration resistant prostate cancer

1 November 2017 | | URO - Urologic Oncology
Castrate resistant prostate cancer (CRPC) is defined by disease progression despite androgen-deprivation therapy lowering testosterone to castrate levels. It may present as a rise in serum levels of prostate specific antigen (PSA), progression of pre-existing disease, or the appearance of...

Focal therapy for prostate cancer – ready for prime time?

1 November 2016 | | URO - Basic Science Research, URO - Urologic Oncology
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...

Prostate cancer survivorship: a new path for uro-oncology

1 July 2015 | | URO - Urologic Oncology
Over two million people in England have a diagnosis of cancer [1]. Of this figure, over 250,000 have been diagnosed with prostate cancer [2]. However, during the next decade, a rapid increase in the number of new cancer diagnoses, as...

The role of transperineal template biopsies in the diagnosis of prostate cancer

1 March 2014 | | URO - Urologic Oncology
The case In 2002, Mr A, a 64-year-old software engineer, was referred by his GP for further investigation of a raised prostate specific antigen (PSA) of 6.2. His prostate felt benign. He underwent transrectal ultrasound guided (TRUS) prostate biopsies. This...

MRI screening for prostate cancer: a step towards a ‘prostagram’

7 January 2020 | | URO - Urologic Oncology, URO - Technology
The UK National Screening Committee has been calling for further research into alternative screening tests for prostate cancer. The committee decided against prostate cancer screening using prostate specific antigen (PSA) testing on the basis that “PSA is still a poor...

The role of PET-CT imaging in prostate cancer

4 October 2021 | | URO - Urologic Oncology
Prostate cancer (PCa) is the second most common cancer in the UK, with 43,000 cases in 2017-18 [1,2]. Accurate primary staging and the detection of suspected recurrence following treatment is vital for directing management and predicting prognosis. This has conventionally...